Dupixent clears PhIII trial in new disease as blockbuster looks to expand past Regeneron-Sanofi split
Sanofi and Regeneron may be splitting up, but their billion-dollar baby, Dupixent, keeps on growing.
Already grossing over $2 billion last year based on FDA approvals for asthma and atopic dermatitis and a form of rhinosinusitis, Dupixent may be nearing a fourth indication: Eosinophilic esophagitis (EoE), an inflammatory disease marked by the buildup of white blood cells in the esophagus and which affects around 160,000 US patients annually.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
